- Conditions
- Peripheral Vascular Disease
- Interventions
- Misago™ Self-Expanding Stent System
- Device
- Lead sponsor
- Terumo Medical Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2016
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Little Rock, Arkansas + 27 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 5,346
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
- Interventions
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radionuclide Imaging, Selpercatinib, X-Ray Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 172
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
- Conditions
- Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
- Interventions
- cilengitide, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 19
- States / cities
- Oakland, California • San Francisco, California • Washington D.C., District of Columbia + 16 more
- Conditions
- Heart Failure, Congestive, Ventricular Dysfunction, Cardiomyopathies
- Interventions
- Thoratec HeartMate II Left Ventricular Assist System (LVAS)
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- Not listed
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 30 more
- Conditions
- Abdominal Aortic Aneurysm
- Interventions
- AFX EVAR AAA Graft System, FDA Approved EVAR AAA Graft Systems
- Device
- Lead sponsor
- Endologix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 56
- States / cities
- Florence, Alabama • Huntsville, Alabama • Phoenix, Arizona + 49 more
- Conditions
- Peripheral Arterial Disease
- Interventions
- Turbo Elite Laser and Turbo Tandem Laser Guide Catheters, Balloon angioplasty
- Device · Procedure
- Lead sponsor
- Spectranetics Corporation
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Little Rock, Arkansas + 28 more
- Conditions
- Small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer
- Interventions
- Guadecitabine, Carboplatin
- Drug
- Lead sponsor
- Shadia Jalal, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Muncie, Indiana • Charlottesville, Virginia + 1 more
- Conditions
- Carcinoma, Pancreatic Ductal, Pancreatic Cancer, Pancreatic Disease
- Interventions
- AGS-1C4D4, Gemcitabine
- Biological
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 15
- States / cities
- La Jolla, California • Boynton Beach, Florida • Miami, Florida + 12 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia
- Interventions
- Azacitidine, Cytarabine, Decitabine, Laboratory Biomarker Analysis, Midostaurin, Nivolumab
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 60 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 506
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 337 more
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
- Interventions
- Bevacizumab, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,873 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 614
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 395 more
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation (TUNA) Therapy, Finasteride and Alfuzosin
- Device · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Chicago, Illinois • Rochester, Minnesota + 4 more
- Conditions
- Atrial Fibrillation
- Interventions
- Edoxaban-based Regimen, VKA-based Regimen
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 60 more
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Genio™ system
- Device
- Lead sponsor
- Nyxoah S.A.
- Industry
- Eligibility
- 22 Years to 75 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Boca Raton, Florida • Tampa, Florida + 12 more
- Conditions
- Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, AML, MDS, NHL
- Interventions
- AMG 397, Dexamethasone, Azacitidine
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 9 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
- Interventions
- Bevacizumab, Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
- Biological · Other · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 5
- States / cities
- Westwood, Kansas • Detroit, Michigan • Buffalo, New York + 2 more
- Conditions
- Osteoporosis, Prostate Cancer
- Interventions
- Calcium, Zoledronic acid, radiation therapy, LHRH, Vitamin D
- Dietary Supplement · Radiation · Drug
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 80
- States / cities
- Chico, California • Los Angeles, California • Pomona, California + 66 more
- Conditions
- Smoking
- Interventions
- varenicline, Individual smoking cessation counseling
- Drug · Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Madison, Wisconsin • Milwaukee, Wisconsin
- Conditions
- Prostate Cancer, Bone Metastases, Prostate Neoplasms
- Interventions
- LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride
- Drug · Radiation
- Lead sponsor
- Ajjai Alva, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Peoria, Illinois • Indianapolis, Indiana + 8 more
- Conditions
- Myasthenia Gravis
- Interventions
- thymectomy plus prednisone, prednisone alone
- Procedure · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
- Conditions
- Carotid Artery Disease
- Interventions
- Xact Stent with either Emboshield Pro (Gen 5) or Emboshield (Gen 3)
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 322 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 38
- States / cities
- Fremont, California • Mountain View, California • Newport Beach, California + 35 more
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- ATA188, Placebo
- Biological · Drug
- Lead sponsor
- Atara Biotherapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 25
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 22 more
- Conditions
- Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
- Interventions
- Biopsy Procedure, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Magnetic Resonance Elastography, Positron Emission Tomography, Radiation Therapy, Vincristine
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 166
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 129 more
- Conditions
- Aging
- Interventions
- Memory decision type
- Behavioral
- Lead sponsor
- Caitlin Bowman
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- End-Stage Heart Failure, Bridge-to-Transplant LVAD Placement (BTT), Destination Therapy LVAD Placement (DT), Refusal of LVAD Placement (Decliners), LVAD Caregivers
- Interventions
- LVAD Decision Aid
- Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 7
- States / cities
- New Orleans, Louisiana • Cleveland, Ohio • Oklahoma City, Oklahoma + 2 more